Clinical Trial Update: SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002) [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial comparing SCH 54031 PEG12000 interferon alfa-2b (PEG Intron) to INTRON A as adjuvant therapy for melanoma was terminated with posted results i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• INTRON A (SCH 30500, MK-2958) (interferon alfa-2b)
• SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) (interferon alfa-2b PEGylated)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Melanoma | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2019-07-24